Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
103
-
Total 13F shares, excl. options
-
64.3M
-
Shares change
-
+5.32M
-
Total reported value, excl. options
-
$1.3B
-
Value change
-
+$105M
-
Put/Call ratio
-
0.03
-
Number of buys
-
53
-
Number of sells
-
-45
-
Price
-
$20.14
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q4 2022
127 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q4 2022.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 103 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 64.3M shares
of 72.2M outstanding shares and own 89.08% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (9.2M shares), FMR LLC (7.91M shares), Avidity Partners Management LP (5.15M shares), VANGUARD GROUP INC (4.16M shares), WELLINGTON MANAGEMENT GROUP LLP (3.62M shares), BlackRock Inc. (3.47M shares), STATE STREET CORP (3.08M shares), Capital International Investors (3.05M shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (2.23M shares), and T. Rowe Price Investment Management, Inc. (2.21M shares).
This table shows the top 103 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.